New ALS drug shows promise in Mid-Stage trial
Disease control
Ongoing
This study tests a new drug called NX210c in 80 adults with ALS, a nerve disease that weakens muscles over time. Participants receive multiple IV infusions of the drug or a placebo to see if it slows the disease and is safe. The main focus is on changes in blood markers that refl…
Phase: PHASE2 • Sponsor: Axoltis Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC